全球基因組編輯市場規模、佔有率、趨勢和成長分析報告（2026-2034）

基因組編輯市場預計將從 2025 年的 88.1 億美元成長到 2034 年的 289.6 億美元，2026 年至 2034 年的複合年成長率為 14.14%。

受基因工程技術進步的推動，全球基因組編輯市場正經歷顯著成長。諸如基於CRISPR的系統等工具能夠對DNA序列進行精確修改，用於研究和治療目的。人們對基因治療、農業生物技術和疾病建模日益成長的興趣也促進了市場擴張。生物技術研究投入的增加正在加速進一步的創新。

主要成長要素包括對個人化醫療和遺傳疾病治療日益成長的需求。製藥公司正在推進基因組編輯技術在標靶治療的研究。已開發地區政府的資金投入和法規環境的改善正在加強相關研究活動。此外，作物改良和畜牧育種等領域的廣泛應用也促進了市場成長。

技術進步提高了基因編輯的精確度和安全性，從而為未來發展奠定了堅實的基礎。新興市場對生物技術基礎設施的投資將創造新的機會。倫理考慮和監管趨勢預計將影響市場動態。隨著基因研究的不斷發展，全球基因組編輯市場預計將持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球基因組編輯市場：依技術分類

• 市場分析、洞察與預測
• CRISPR/Cas9
• TALENs/MegaTALs
• 主編
• 低音編輯
• Cpf1（源自普雷沃氏菌屬和弗朗西斯氏菌屬的 CRISPR 1）
• CasX 和 CasY
• ZFN
• Meganucleases
• 寡核苷酸誘導突變（ODM）
• 合成基因編輯工具
• 轉錄活化因子樣效應器低音編輯器 (TALE-BE)
• 其他

第5章 全球基因組編輯市場：依交付方式分類

• 市場分析、洞察與預測
• Ek Vivo
• 體內

第6章 全球基因組編輯市場：依應用領域分類

• 市場分析、洞察與預測
• 基因工程（細胞株工程、動物基因工程、植物性因工程等）
• 臨床應用（診斷、治療研發）
• 其他

第7章 全球基因組編輯市場：依最終用途分類

• 市場分析、洞察與預測
• 生物技術和製藥公司
• 學術研究機構與政府研究機構
• 受託研究機構

第8章：全球基因組編輯市場：依模式分類

• 市場分析、洞察與預測
• 合約
• 內部開發

第9章 全球基因組編輯市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Merck KGaA
  • Cibus Inc
  • Recombinetics
  • Sangamo Therapeutics
  • Editas Medicine
  • Precision Biosciences
  • CRISPR Therapeutics
  • Intellia Therapeutics Inc
  • Caribou Biosciences Inc
  • Cellectis SA
  • AstraZeneca
  • Takara Bio Inc
  • Horizon Discovery Ltd.（Revvity Inn Inc.）

The Genome Editing Market size is expected to reach USD 28.96 Billion in 2034 from USD 8.81 Billion (2025) growing at a CAGR of 14.14% during 2026-2034.

The Global Genome Editing Market is witnessing significant growth driven by advancements in genetic engineering technologies. Tools such as CRISPR-based systems are enabling precise modification of DNA sequences for research and therapeutic purposes. Increasing focus on gene therapy, agricultural biotechnology, and disease modeling is supporting market expansion. Rising investments in biotechnology research are further accelerating innovation.

Major growth drivers include growing demand for personalized medicine and treatment of genetic disorders. Pharmaceutical companies are exploring genome editing for targeted therapies. Government funding and supportive regulatory frameworks in developed regions are strengthening research activities. Additionally, expanding applications in crop improvement and livestock breeding are contributing to market growth.

Future prospects remain strong as technological advancements improve editing accuracy and safety. Emerging markets investing in biotechnology infrastructure will present new opportunities. Ethical considerations and regulatory developments will shape market dynamics. As genetic research continues to evolve, the Global Genome Editing Market is projected to experience sustained expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• CRISPR/Cas9
• TALENs/MegaTALs
• Prime Editing
• Base Editing
• Cpf1 (CRISPR from Prevotella and Francisella 1)
• CasX and CasY
• ZFN
• Meganucleases
• Oligonucleotide-Directed Mutagenesis (ODM)
• Synthetic Gene Editors
• Transcription Activator-Like Effector Base Editors (TALE-BE)
• Other

By Delivery Method

• Ex-vivo
• In-vivo

By Application

• Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others)
• Clinical Applications (Diagnostics, Therapy Development)
• Others

By End-use

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations

By Mode

• Contract
• In-House

COMPANIES PROFILED

• Merck KGaA, Cibus Inc, Recombinetics, Sangamo Therapeutics, Editas Medicine, Precision Biosciences, CRISPR Therapeutics, Intellia Therapeutics Inc, Caribou Biosciences Inc, Cellectis SA, AstraZeneca, Takara Bio Inc, Horizon Discovery Ltd Revvity Inn Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENOME EDITING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. CRISPR/Cas9 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. TALENs/MegaTALs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Prime Editing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Base Editing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Cpf1 (CRISPR from Prevotella and Francisella 1) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. CasX and CasY Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. ZFN Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Meganucleases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.10. Oligonucleotide-Directed Mutagenesis (ODM) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.11. Synthetic Gene Editors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.12. Transcription Activator-Like Effector Base Editors (TALE-BE) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.13. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENOME EDITING MARKET: BY DELIVERY METHOD 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Delivery Method
• 5.2. Ex-vivo Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. In-vivo Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENOME EDITING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinical Applications (Diagnostics, Therapy Development) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENOME EDITING MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Biotechnology and Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Academic and Government Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GENOME EDITING MARKET: BY MODE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Mode
• 8.2. Contract Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. In-House Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL GENOME EDITING MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Technology
  • 9.2.2 By Delivery Method
  • 9.2.3 By Application
  • 9.2.4 By End-use
  • 9.2.5 By Mode
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Technology
  • 9.3.2 By Delivery Method
  • 9.3.3 By Application
  • 9.3.4 By End-use
  • 9.3.5 By Mode
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Technology
  • 9.4.2 By Delivery Method
  • 9.4.3 By Application
  • 9.4.4 By End-use
  • 9.4.5 By Mode
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Technology
  • 9.5.2 By Delivery Method
  • 9.5.3 By Application
  • 9.5.4 By End-use
  • 9.5.5 By Mode
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Technology
  • 9.6.2 By Delivery Method
  • 9.6.3 By Application
  • 9.6.4 By End-use
  • 9.6.5 By Mode
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL GENOME EDITING INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Merck KGaA
  • 11.2.2 Cibus Inc
  • 11.2.3 Recombinetics
  • 11.2.4 Sangamo Therapeutics
  • 11.2.5 Editas Medicine
  • 11.2.6 Precision Biosciences
  • 11.2.7 CRISPR Therapeutics
  • 11.2.8 Intellia Therapeutics Inc
  • 11.2.9 Caribou Biosciences Inc
  • 11.2.10 Cellectis S.A
  • 11.2.11 AstraZeneca
  • 11.2.12 Takara Bio Inc
  • 11.2.13 Horizon Discovery Ltd. (Revvity Inn Inc.)